Repligen: Ongoing Bioprocessing Market Recovery
Portfolio Pulse from
Repligen is experiencing a strong recovery in the bioprocessing market, with a 'buy' rating and a one-year price target of $175. The company reported 3% organic revenue growth and 13% growth in non-COVID business, with record-high order intakes. The acquisition of 908 Devices' bioprocessing analytics portfolio enhances its offerings.
March 20, 2025 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Repligen is rated a 'buy' with a $175 price target due to strong bioprocessing market recovery. The company shows 3% organic revenue growth and 13% growth in non-COVID business, with record-high order intakes. The acquisition of 908 Devices' portfolio enhances its offerings.
Repligen's strong market recovery and growth in non-COVID business, along with strategic acquisition, are positive indicators for its stock. The 'buy' rating and price target suggest confidence in its future performance.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100